These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 32302790)

  • 21. Salvage Radiotherapy Versus Hormone Therapy for Prostate-specific Antigen Failure After Radical Prostatectomy: A Randomised, Multicentre, Open-label, Phase 3 Trial (JCOG0401)
    Yokomizo A; Wakabayashi M; Satoh T; Hashine K; Inoue T; Fujimoto K; Egawa S; Habuchi T; Kawashima K; Ishizuka O; Shinohara N; Sugimoto M; Yoshino Y; Nihei K; Fukuda H; Tobisu KI; Kakehi Y; Naito S;
    Eur Urol; 2020 Jun; 77(6):689-698. PubMed ID: 31866092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621.
    Hurwitz MD; Harris J; Sartor O; Xiao Y; Shayegan B; Sperduto PW; Badiozamani KR; Lawton CAF; Horwitz EM; Michalski JM; Roof K; Beyer DC; Zhang Q; Sandler HM
    Cancer; 2017 Jul; 123(13):2489-2496. PubMed ID: 28323339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT.
    Hamdy FC; Elliott D; le Conte S; Davies LC; Burns RM; Thomson C; Gray R; Wolstenholme J; Donovan JL; Fitzpatrick R; Verrill C; Gleeson F; Singh S; Rosario D; Catto JW; Brewster S; Dudderidge T; Hindley R; Emara A; Sooriakumaran P; Ahmed HU; Leslie TA
    Health Technol Assess; 2018 Sep; 22(52):1-96. PubMed ID: 30264692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Systematic Review of Focal Ablative Therapy for Clinically Localised Prostate Cancer in Comparison with Standard Management Options: Limitations of the Available Evidence and Recommendations for Clinical Practice and Further Research.
    Bates AS; Ayers J; Kostakopoulos N; Lumsden T; Schoots IG; Willemse PM; Yuan Y; van den Bergh RCN; Grummet JP; van der Poel HG; Rouvière O; Moris L; Cumberbatch MG; Lardas M; Liew M; Van den Broeck T; Gandaglia G; Fossati N; Briers E; De Santis M; Fanti S; Gillessen S; Oprea-Lager DE; Ploussard G; Henry AM; Tilki D; van der Kwast TH; Wiegel T; N'Dow J; Mason MD; Cornford P; Mottet N; Lam TBL
    Eur Urol Oncol; 2021 Jun; 4(3):405-423. PubMed ID: 33423943
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence.
    Marconi L; Stonier T; Tourinho-Barbosa R; Moore C; Ahmed HU; Cathelineau X; Emberton M; Sanchez-Salas R; Cathcart P
    Eur Urol; 2019 Jul; 76(1):27-30. PubMed ID: 30904357
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Locally advanced prostate cancer: definition, prognosis and treatment].
    Plantade A; Massard C; de Crevoisier R; Fizazi K
    Bull Cancer; 2007 Jul; 94(7 Suppl):F50-61. PubMed ID: 17845994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.
    Hamdy FC; Donovan JL; Lane JA; Mason M; Metcalfe C; Holding P; Wade J; Noble S; Garfield K; Young G; Davis M; Peters TJ; Turner EL; Martin RM; Oxley J; Robinson M; Staffurth J; Walsh E; Blazeby J; Bryant R; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Paul A; Paez E; Powell P; Prescott S; Rosario D; Rowe E; Neal D
    Health Technol Assess; 2020 Aug; 24(37):1-176. PubMed ID: 32773013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial.
    Tosco L; Laenen A; Gevaert T; Salmon I; Decaestecker C; Davicioni E; Buerki C; Claessens F; Swinnen J; Goffin K; Oyen R; Everaerts W; Moris L; De Meerleer G; Haustermans K; Joniau S;
    BMC Cancer; 2018 Apr; 18(1):354. PubMed ID: 29606109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.
    Nair B; Wilt T; MacDonald R; Rutks I
    Cochrane Database Syst Rev; 2002; (1):CD003506. PubMed ID: 11869665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial.
    De Bruycker A; Spiessens A; Dirix P; Koutsouvelis N; Semac I; Liefhooghe N; Gomez-Iturriaga A; Everaerts W; Otte F; Papachristofilou A; Scorsetti M; Shelan M; Siva S; Ameye F; Guckenberger M; Heikkilä R; Putora PM; Zapatero A; Conde-Moreno A; Couñago F; Vanhoutte F; Goetghebeur E; Reynders D; Zilli T; Ost P
    BMC Cancer; 2020 May; 20(1):406. PubMed ID: 32398040
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant hormonal treatment - the bicalutamide early prostate cancer program.
    Wirth MP; Hakenberg OW; Froehner M
    Front Radiat Ther Oncol; 2008; 41():39-48. PubMed ID: 18544984
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial).
    Brouquet A; Bachet JB; Huguet F; Karoui M; Artru P; Sabbagh C; Lefèvre JH; Vernerey D; Mariette C; Vicaut E; Benoist S;
    BMC Cancer; 2020 May; 20(1):485. PubMed ID: 32471382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial.
    Solberg A; Haugen OA; Viset T; Bergh A; Tasdemir I; Ahlgren G; Widmark A; Angelsen A
    Int J Radiat Oncol Biol Phys; 2011 May; 80(1):55-61. PubMed ID: 20598453
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade.
    McKay RR; Montgomery B; Xie W; Zhang Z; Bubley GJ; Lin DW; Preston MA; Trinh QD; Chang P; Wagner AA; Mostaghel EA; Kantoff PW; Nelson PS; Kibel AS; Taplin ME
    Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):364-372. PubMed ID: 29263420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of androgen deprivation therapy in early salvage radiation among patients with prostate-specific antigen level of 0.5 or less.
    Parekh A; Chen MH; Graham P; Mahal BA; Hirsch AE; Nakabayashi M; Evan C; Kantoff PW; Martin NE; Nguyen PL
    Clin Genitourin Cancer; 2015 Feb; 13(1):e1-6. PubMed ID: 25103271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liver resection surgery compared with thermal ablation in high surgical risk patients with colorectal liver metastases: the LAVA international RCT.
    Davidson B; Gurusamy K; Corrigan N; Croft J; Ruddock S; Pullan A; Brown J; Twiddy M; Birtwistle J; Morris S; Woodward N; Bandula S; Hochhauser D; Prasad R; Olde Damink S; Coolson M; Laarhoven KV; de Wilt JH
    Health Technol Assess; 2020 Apr; 24(21):1-38. PubMed ID: 32370822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Triggers and oncologic outcome of salvage radical prostatectomy, salvage radiotherapy and active surveillance after focal therapy of prostate cancer.
    von Hardenberg J; Cash H; Koch D; Borkowetz A; Bruendl J; Leyh-Bannurah SR; Kuru TH; Kowalewski KF; Schindele D; Mala KS; Westhoff N; Blana A; Schostak M;
    World J Urol; 2021 Oct; 39(10):3747-3754. PubMed ID: 33881557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multimodal treatment in focal therapy for localized prostate cancer using concomitant short-term androgen deprivation therapy: the ENHANCE prospective pilot study.
    Marra G; Dell'oglio P; Baghdadi M; Cathelineau X; Sanchez-Salas R;
    Minerva Urol Nefrol; 2019 Oct; 71(5):544-548. PubMed ID: 31508924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.